Furthermore, the presence of PV in the BARD1 gene introduces the possibility of incorporating PARP inhibitors (Poly (ADP-ribose) polymerase inhibitors) as therapeutic agents, patients benefit from this treatment that originally targeted other forms of HBOC with pathogenic mutations in genes such as BRCA1 and PALB2 [43]. This evidence concerns the gene BRCA1 and acquired polycythemia vera.